AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2018
Mar 5, 2018
31523_dirs_2018-03-05_e04669e8-ed99-44c8-a3f6-293b2392b696.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS INC (FOLD)
CIK: 0001178879
Period of Report: 2018-03-01
Reporting Person: Quimi Daphne (SVP, Finance)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-03-01 | Common stock | M | 8149 | $4.16 | Acquired | 72481 | Direct |
| 2018-03-01 | Common stock | S | 8149 | $14.0553 | Disposed | 64332 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-03-01 | Stock Options (right to buy) | $4.16 | M | 8149 | Disposed | 2019-11-16 | Common stock (8149) | Direct |
Footnotes
F1: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017.
F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.11 to $14.53. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: All of the options were fully vested and exercisable as of March 1, 2018.